Literature DB >> 26752745

Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.

Yuji Sakuma1, Hirotaka Nishikiori2, Sachie Hirai1, Miki Yamaguchi1, Gen Yamada2, Atsushi Watanabe3, Tadashi Hasegawa4, Takashi Kojima5, Toshiro Niki6, Hiroki Takahashi2.   

Abstract

The secondary epidermal growth factor receptor (EGFR) T790M mutation is the most prominent mechanism that confers resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in lung cancer treatment. Although third-generation EGFR TKIs can suppress the kinase activity of T790M-positive EGFR, they still cannot eradicate EGFR-mutated cancer cells. We previously reported that a subpopulation of EGFR-mutant lung adenocarcinomas depends on enhanced autophagy, instead of EGFR, for survival, and in this study we explore another mechanism that contributes to TKI resistance. We demonstrate here that an EGFR-mutant lung adenocarcinoma cell line, H1975 (L858R+T790M), has a subset of cells that exhibits an epithelial-mesenchymal transition (EMT) phenotype and can thrive in the presence of third-generation EGFR TKIs. These cells depend on not only autophagy but also on the isomerase Pin1 for survival in vitro, unlike their parental cells. The Pin1 protein was expressed in an EGFR-mutant lung cancer tissue that has undergone partial EMT and acquired resistance to EGFR TKIs, but not its primary tumor. These findings suggest that inhibition of Pin1 activity can be a novel strategy in lung cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26752745     DOI: 10.1038/labinvest.2015.155

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  28 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Authors:  Man-Li Luo; Chang Gong; Chun-Hau Chen; Daniel Y Lee; Hai Hu; Pengyu Huang; Yandan Yao; Wenjun Guo; Ferenc Reinhardt; Gerburg Wulf; Judy Lieberman; Xiao Zhen Zhou; Erwei Song; Kun Ping Lu
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

3.  Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay.

Authors:  Shoichi Matsukuma; Mitsuyo Yoshihara; Fumio Kasai; Akinori Kato; Akira Yoshida; Makoto Akaike; Osamu Kobayashi; Haruhiko Nakayama; Yuji Sakuma; Tsutomu Yoshida; Yoichi Kameda; Eiju Tsuchiya; Yohei Miyagi
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

Review 5.  Role of prolyl isomerase pin1 in pathogenesis of diseases and remedy for the diseases from natural products.

Authors:  Katsuhiko Takahashi; Taiki Shimizu; Keita Kosaka; Masafumi Hidaka; Chiyoko Uchida; Takafumi Uchida
Journal:  Curr Drug Targets       Date:  2014       Impact factor: 3.465

6.  WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.

Authors:  Yuji Sakuma; Yukiko Yamazaki; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Shoichi Matsukuma; Haruhiko Nakayama; Tomoyuki Yokose; Yoichi Kameda; Shiro Koizume; Yohei Miyagi
Journal:  Lab Invest       Date:  2011-12-12       Impact factor: 5.662

Review 7.  The dynamic nature of autophagy in cancer.

Authors:  Alec C Kimmelman
Journal:  Genes Dev       Date:  2011-10-01       Impact factor: 11.361

Review 8.  NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.

Authors:  Tomoya Yamaguchi; Yasuyuki Hosono; Kiyoshi Yanagisawa; Takashi Takahashi
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

9.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Authors:  Annette O Walter; Robert Tjin Tham Sjin; Henry J Haringsma; Kadoaki Ohashi; Jing Sun; Kwangho Lee; Aleksandr Dubrovskiy; Matthew Labenski; Zhendong Zhu; Zhigang Wang; Michael Sheets; Thia St Martin; Russell Karp; Dan van Kalken; Prasoon Chaturvedi; Deqiang Niu; Mariana Nacht; Russell C Petter; William Westlin; Kevin Lin; Sarah Jaw-Tsai; Mitch Raponi; Terry Van Dyke; Jeff Etter; Zoe Weaver; William Pao; Juswinder Singh; Andrew D Simmons; Thomas C Harding; Andrew Allen
Journal:  Cancer Discov       Date:  2013-09-24       Impact factor: 39.397

10.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

View more
  10 in total

Review 1.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

Review 2.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Authors:  Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Rev Cancer       Date:  2016-06-03       Impact factor: 60.716

Review 3.  Understanding the role of PIN1 in hepatocellular carcinoma.

Authors:  Chi-Wai Cheng; Ka-Wai Leong; Eric Tse
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

Review 4.  Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.

Authors:  Jing Xu; Jinghui Wang; Shucai Zhang
Journal:  Oncotarget       Date:  2017-09-22

5.  Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.

Authors:  Toshiyuki Sumi; Sachie Hirai; Miki Yamaguchi; Yusuke Tanaka; Makoto Tada; Gen Yamada; Tadashi Hasegawa; Yohei Miyagi; Toshiro Niki; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

Review 6.  [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].

Authors:  Lianfang Ni; Ligong Nie
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

7.  Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells.

Authors:  Hsiang-Hao Chuang; Jui-Feng Hsu; Hsu-Liang Chang; Pei-Hui Wang; Po-Ju Wei; Da-Wei Wu; Ming-Shyan Huang; Michael Hsiao; Chih-Jen Yang
Journal:  Int J Med Sci       Date:  2020-09-21       Impact factor: 3.738

Review 8.  Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.

Authors:  Ana I Velazquez; Caroline E McCoach
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

9.  Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma.

Authors:  Miki Yamaguchi; Sachie Hirai; Toshiyuki Sumi; Yusuke Tanaka; Makoto Tada; Yukari Nishii; Tadashi Hasegawa; Hiroaki Uchida; Gen Yamada; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Biochem Biophys Res Commun       Date:  2017-04-20       Impact factor: 3.575

Review 10.  The Autophagic Route of E-Cadherin and Cell Adhesion Molecules in Cancer Progression.

Authors:  Manuela Santarosa; Roberta Maestro
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.